NCT02451553View on ClinicalTrials.gov

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 5, 2015

Primary Completion Date

April 16, 2022

Study Completion Date

April 16, 2022

Conditions

Advanced Malignant Solid NeoplasmBile Duct CarcinomaRecurrent Malignant Solid NeoplasmRecurrent Pancreatic CarcinomaStage III Pancreatic Cancer AJCC v6 and v7Stage IVA Pancreatic CancerStage IVB Pancreatic Cancer

Interventions

DRUG

Afatinib Dimaleate

Given PO

DRUG

Capecitabine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

lead

University of Washington

OTHER

NCT02451553 - Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | Biotech Hunter | Biotech Hunter